Please login to the form below

Not currently logged in
Email:
Password:

HBV

This page shows the latest HBV news and features for those working in and with pharma, biotech and healthcare.

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B

Around a third of all the 350 to 400 million people infected with HBV worldwide are in China, with many unaware they are carrying the virus. ... HBV can be treated effectively with antiviral drugs but so far no cure has been developed, meaning that there

Latest news

  • Gilead targets hep B in half a billion dollar deal with Precision BioSciences Gilead targets hep B in half a billion dollar deal with Precision BioSciences

    Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program. ... We look forward to exploring this [Precision BioScience’s genome editing] technology as an important

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... In Europe, a WHO report from 2016 showed that 13 million

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of adults and adolescents ... The CHMP's recommendation follows the

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    Meanwhile, Gilead has also reported positive news in the area of hepatitis B virus (HBV) therapy, revealing that its tenofovir alafenamide fumarate (TAF) candidate had hit its objectives in two phase ... The trials involved treatment-naïve and

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    Acquires Philadelphia-based Novira therapeutics. Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection. ... and disrupts the HBV lifecycle by inducing the

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on. ... the TRiM platform, for chronic HBV infection. Licence. $3.7B. Endocyte /. Novartis. Radiopharmaceuticals and drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with chronic hepatitis B virus (HBV) infection.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics